Patients in the group with high cystatin-C values (>0.637 mg/L) had a significantly higher rate of MACCE (major adverse cardiac and cerebrovascular events, composed of CV death, ACS, stroke, and CHF hospitalization) after a 63-month median follow-up on multivariate analysis [55]. The gene discussed is CST3; the disease is stroke disorder.